The Week in Review: September 12-16

From ketamine response to differences between mTBI and concussion, here are highlights from the week in Psychiatric Times.

Chepko Danil_AdobeStock

This week, Psychiatric TimesTM covered a wide variety of psychiatric issues and industry updates, from important suicide prevention tips to new insights into ketamine response. Here are some highlights from the week.

Study Explores Effects of Experimenter Sex on Ketamine Response


Does a health care provider’s sex impact how well active agents perform? The answer appears to be a “yes,” according to a new study that examined the antidepressant response to ketamine and its bioactive metabolite (2R,6R)-hydroxynorketamine when the drug was administered to mice by men compared to women. Continue Reading

Suicide Prevention Month Tips and Insights


September is National Suicide Prevention Month. In this Mental Health Minute, Susan J. Noonan, MD, MPH, of McLean Hospital and Massachusetts General Hospital shares the risk factors and warning signs of suicide that clinicians must know. Watch Here

Differentiating mTBI/Concussion


A traumatic brain injury (TBI) occurs when brain function is altered due to an external blow to the head or body. National surveillance data indicates there are approximately 3 million new cases of TBI each year in the United States, and that the incidence of TBI has been increasing since 1995. Rates of TBI are increasing in all age groups, but particularly for adults over the age of 65, primarily due to falls. According to some estimates, mild traumatic brain injury (mTBI), or concussion, accounts for as many as 75% to 90% of all traumatic brain injuries. Continue Reading

NDA for Long-Acting Injectable for Schizophrenia and Bipolar I Accepted


The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults. It is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. Continue Reading

See more recent coverage from Psychiatric TimesTM here. And be sure to stay up-to-date by subscribing to the Psychiatric TimesTM E-newsletter.

Do you have a comment on any of these or other articles? Have a good idea for an article and want to write? Interested in sharing your perspectives? Write to us at

Related Videos
View All
© 2023 MJH Life Sciences

All rights reserved.